PDRN CareNucleoside Metabolism
Dr. Sarah Chen
PhD, Molecular Biology
Nucleoside metabolism encompasses the biochemical pathways by which cells synthesize, interconvert, and recycle nucleosides β the molecular building blocks of DNA and RNA [1,3].
Definition
Nucleoside metabolism encompasses the biochemical pathways by which cells synthesize, interconvert, and recycle nucleosides β the molecular building blocks of DNA and RNA [1][3]. A nucleoside consists of a nitrogenous base (adenine, guanine, cytosine, or thymine for DNA; uracil replaces thymine in RNA) attached to a sugar molecule (deoxyribose for DNA, ribose for RNA). When phosphorylated, nucleosides become nucleotides, the monomeric units that are polymerized into nucleic acid strands during DNA replication and RNA transcription [3]. Understanding nucleoside metabolism is fundamental to appreciating how PDRN functions as a regenerative therapy.
De Novo Synthesis
The de novo pathway builds nucleotides from scratch using small precursor molecules β amino acids (glycine, aspartate, glutamine), CO2, and tetrahydrofolate derivatives [3]. Purine synthesis (producing adenine and guanine nucleotides) requires 10 enzymatic steps and consumes 6 high-energy phosphate bonds per nucleotide. Pyrimidine synthesis (producing cytosine and thymine nucleotides) is somewhat less costly but still demands significant metabolic investment [1][3]. De novo synthesis occurs primarily in the liver and is the dominant pathway in rapidly dividing cells with ample metabolic resources. However, it is energy-intensive β a limitation that becomes significant in tissues under metabolic stress, such as aged, damaged, or ischemic skin where ATP availability is reduced [2].
The Salvage Pathway
The salvage pathway provides a metabolically economical alternative by recycling free bases and nucleosides released from DNA and RNA degradation [1][3]. Key salvage enzymes include hypoxanthine-guanine phosphoribosyltransferase (HGPRT) for purines and thymidine kinase (TK) for pyrimidines, which convert free bases or nucleosides back into active nucleotides using a single phosphoribosyl transfer or phosphorylation step [3]. The salvage pathway consumes far less ATP than de novo synthesis β typically just one or two high-energy bonds compared to six or more β making it the preferred nucleotide source for cells with limited energy reserves [1].
Nucleoside Metabolism in Skin
Skin cells, particularly dermal fibroblasts and basal keratinocytes, rely on both pathways to maintain nucleotide pools for DNA repair, replication, and gene expression [2][4]. In youthful, healthy skin, the balance between de novo and salvage pathways adequately supplies the nucleotides needed for normal cell turnover and ongoing collagen synthesis. In aged or damaged skin, several factors compromise nucleotide availability: reduced mitochondrial function lowers ATP production, making the energy-intensive de novo pathway less efficient; chronic UV-induced DNA damage increases the demand for repair nucleotides; and decreased blood supply limits the delivery of precursor amino acids and cofactors [2]. This nucleotide deficit creates a bottleneck β even when fibroblasts receive growth signals, they cannot fully respond if they lack the raw materials for DNA synthesis and cell division.
PDRN and the Salvage Pathway
PDRN's connection to nucleoside metabolism is direct and mechanistically important [2][4]. When PDRN β a polymer of deoxyribonucleotides β is applied to tissue, extracellular nucleases progressively cleave the polymer into oligonucleotides, then into individual deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxycytidine, and thymidine) [2]. These free deoxyribonucleosides are taken up by surrounding cells and enter the salvage pathway, where they are phosphorylated into active deoxyribonucleotide triphosphates (dNTPs) ready for incorporation into new DNA strands [2][4].
This salvage-pathway feeding has two important consequences for tissue regeneration:
Removing the metabolic bottleneck β By providing pre-formed nucleosides, PDRN bypasses the energy-intensive de novo pathway entirely, enabling cells in metabolically compromised tissue (aged skin, wound beds, ischemic areas) to rapidly replenish their dNTP pools without the ATP expenditure that de novo synthesis would require [2].
Enabling the proliferative response β PDRN simultaneously activates fibroblasts through A2A receptor signaling and supplies the nucleotide building blocks those activated fibroblasts need to actually complete DNA replication and divide [2][4]. This dual action β signal plus substrate β distinguishes PDRN from pure growth factors or receptor agonists that stimulate proliferation without addressing substrate limitations.
Balanced Nucleotide Pools
Maintaining balanced ratios among the four dNTPs (dATP, dGTP, dCTP, dTTP) is critical for DNA replication fidelity [1][3]. Imbalanced pools increase mutation rates because DNA polymerases misincorporate the overabundant nucleotide at positions where the scarce nucleotide should be placed. PDRN provides all four deoxyribonucleoside types simultaneously in the natural ratios present in salmon DNA, supporting balanced pool replenishment rather than skewing ratios toward a single nucleotide [4].
Clinical Significance
The salvage pathway connection explains a unique aspect of PDRN therapy that pure signaling molecules cannot replicate: the ability to simultaneously instruct cells to regenerate and provide the molecular fuel to do so [2]. This dual mechanism is especially relevant in clinical scenarios involving metabolically compromised tissue β chronic wounds, post-procedural recovery, photoaged skin, and scar remodeling β where nucleotide scarcity would otherwise limit the regenerative response even in the presence of adequate growth factor signaling [2][4].
References
- [1]Bianchi V, Pontis E, Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem. 1986;261(34):16037-16042. doi:10.1016/S0021-9258(18)66672-4
- [2]Squadrito F, Bitto A, Irrera N, et al.. Pharmacological Activity and Clinical Use of PDRN. Curr Pharm Des. 2017;23(27):3948-3957. doi:10.2174/1381612823666170516153716
- [3]Mathews CK. Deoxyribonucleotide metabolism, mutagenesis and cancer. Nat Rev Cancer. 2015;15(9):528-539. doi:10.1038/nrc3981
- [4]Kim TH, Heo SY, Oh GW, et al.. Applications of Marine-Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering. Mar Drugs. 2021;19(6):296. doi:10.3390/md19060296